« Tester virtuellement avant de traiter réellement. BioTwin crée des jumeaux virtuels humains basés sur l'analyse multi-omics pour une médecine véritablement personnalisée. »
Precision medicine through
virtual twin technology
BioTwin develops AI-powered virtual twins for personalized healthcare,
reducing treatment costs by 40% and improving patient outcomes by 60%.
Key performance indicators
Q4 2025 Results
Revenue growth trajectory
Clinical outcomes
| Metric | Traditional Care | BioTwin Platform | Improvement |
|---|---|---|---|
| Treatment Success Rate | 62% | 89% | +43.5% |
| Average Time to Diagnosis | 21 days | 3 days | -85.7% |
| Cost per Patient | $12,500 | $7,300 | -41.6% |
| Readmission Rate | 18% | 7% | -61.1% |
Core technology
Proprietary AI engine
Our patented virtual twin technology combines multi-modal biomarker analysis with advanced machine learning algorithms trained on 2.3 million patient records.
Competitive advantages
01. Real-Time Processing
Process complex biomarker data in under 3 seconds, enabling immediate clinical decision support.
02. FDA Clearance
First-in-class FDA 510(k) clearance for AI-powered personalized medicine platform.
03. Enterprise Integration
Seamless integration with Epic, Cerner, and other major EHR systems via HL7 FHIR.
04. Regulatory Compliance
HIPAA, GDPR, and ISO 13485 certified with SOC 2 Type II compliance.
Technical specifications
| Processing Capacity | 10,000 concurrent analyses |
| Response Time | < 3 seconds |
| Data Security | AES-256 encryption at rest and in transit |
| API Availability | RESTful API with GraphQL support |
| Deployment Options | Cloud, on-premise, hybrid |
Investment opportunity
Series B funding round
Use of funds
| R&D and Product Development | 40% |
| Market Expansion (US/EU) | 25% |
| Regulatory Approvals | 20% |
| Operations and Infrastructure | 15% |
Market opportunity
Current investors
Strategic partners
Mayo Clinic
Clinical validation and research partnership
Epic Systems
EHR integration and distribution
Microsoft Azure
Cloud infrastructure and AI services
Roche Diagnostics
Biomarker analysis and validation
Request full investment deck
Detailed financial projections, technical documentation, and due diligence materials available under NDA.
Contact Investor Relations